Revolution Medicines, Inc.

Healthcare · Biotechnology · United States

Last price 190.27 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 40.78B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236)...